The data could help the Enhertu regimen overtake a drug combination that’s been used as the initial treatment for ...

The company’s board reiterated its recommendation to instead pursue an offer from SK Capital and Carlyle that’s worth about ...

Alis Biosciences says its goal is to return to investors billions of dollars stuck on the balance sheets of “moribund” ...

The president’s executive order promising to lower pharmaceutical prices includes support for a fix long sought by the ...

The biotech is developing an experimental drug for the most common of a family of disorders all caused by errors in ...

The drug, orforglipron, helped people with diabetes reduce their blood sugar levels while spurring significant weight loss, ...

Commissioner Martin Makary said the agency would, whenever possible, restrict drug company employees from participating as ...

Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump ...

The partners overcame an earlier rejection to win a seventh use for Dupixent, though some analysts are skeptical of its sales ...

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

HHS bypassed normal procedures as it laid off thousands of employees, according to sources. One union has already filed an ...